# AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

> **NCT06106945** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 226 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** AZD0305
- **DRUG:** Elranatamab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06106945
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-05
- **Primary completion:** 2027-08-16
- **Final completion:** 2027-08-16
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106945, "AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT06106945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*